1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited

SBHMY
Sino Biopharmaceutical LimitedUS flagOther OTC
12.49
USD
-1.80
- -
11.13BMarket Cap

Total Valuation

Sino Biopharmaceutical Limited carries a market capitalization of 11.13B, placing it among publicly traded companies globally. Its enterprise value stands at 138.92B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap11.13B
Enterprise Value138.92B

Share Statistics

Sino Biopharmaceutical Limited currently has 18.86B shares outstanding.

Shares Outstanding18.86B
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Sino Biopharmaceutical Limited trades at a trailing price-to-earnings ratio of 12.63. The price-to-sales ratio is 5.00, and the price-to-book ratio stands at 304.79.

PE Ratio12.63
PS Ratio5.00
PB Ratio304.79
P/TBV Ratio4.33
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Sino Biopharmaceutical Limited trades at an EV/EBITDA multiple of 27.65 and an EV/FCF ratio of 526.55. The EV/Sales ratio of 5.48 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 27.65 provides insight into valuation relative to core operating earnings.

EV / Sales5.48
EV / EBITDA27.65
EV / EBIT27.65
EV / FCF526.55

Financial Position

Sino Biopharmaceutical Limited maintains a current ratio of 2.07, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 43.89, indicating elevated leverage, while an interest coverage ratio of 16.96 demonstrates strong ability to service its debt obligations.

Current Ratio2.07
Quick Ratio0.70
Debt / Equity43.89
Debt / EBITDA2.72
Interest Coverage16.96

Financial Efficiency

Sino Biopharmaceutical Limited posts a return on equity of 2,892.08 and a return on invested capital of 8.82.

Return on Equity (ROE)2,892.08
Return on Assets (ROA)16.12
Return on Invested Capital (ROIC)8.82
Return on Capital Employed (ROCE)36.70
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.91

Taxes

Over the trailing twelve months, Sino Biopharmaceutical Limited has paid 1.47B in income taxes, reflecting an effective tax rate of 10.95.

Income Tax1.47B
Effective Tax Rate10.95

Stock Price Statistics

Sino Biopharmaceutical Limited's stock has gained approximately 31.69831% over the past 52 weeks. The 50-day moving average sits at 14.95, while the 200-day moving average is 17.48.

Beta (5Y)N/A
52-Week Price Change31.69831%
50-Day Moving Average14.95
200-Day Moving Average17.48
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Sino Biopharmaceutical Limited generated 25.35B in revenue and converted that into 10.04B in net income, yielding earnings per share of 12.41. EBITDA reached 5.02B, while operating income came in at 5.02B.

Revenue25.35B
Gross Profit20.21B
Operating Income5.02B
Pretax Income13.44B
Net Income10.04B
EBITDA5.02B
EBIT5.02B
Earnings Per Share (EPS)12.41

Balance Sheet

Sino Biopharmaceutical Limited holds 8.03B in cash and equivalents against 13.65B in total debt, resulting in a net debt position of 5.31B. Total book value stands at 415.90M, with working capital of 12.33B providing operational flexibility.

Cash & Cash Equivalents8.03B
Total Debt13.65B
Net Debt5.31B
Equity (Book Value)415.90M
Book Value Per Share0.44
Working Capital12.33B

Margins

Sino Biopharmaceutical Limited operates with a gross margin of 79.71, reflecting its pricing power and cost economics. The operating margin of 19.82 and net profit margin of 39.59 provide insight into operational efficiency.

Gross Margin79.71
Operating Margin19.82
Pretax Margin53.00
Profit Margin39.59
EBITDA Margin19.82

Stock Splits

Sino Biopharmaceutical Limited's most recent stock split took place on August 14, 2020 with a 2:3 split ratio.

Last Split Date8/14/2020
Split Ratio2:3

Scores

Sino Biopharmaceutical Limited posts an Altman Z-Score of 4.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.07